Results 111 to 120 of about 18,508 (192)

Virtual screening and cellular validation of dolutegravir as a BRD9 inhibitor for attenuating pyroptosis in peritoneal mesothelial cells. [PDF]

Ren Fail
Gai J, Xing X, Gong C, Teng Y, Chen S, Yang M, Lou W.   +6 more
europepmc   +1 more source

R263K-associated dolutegravir resistance on tenofovir, lamivudine and dolutegravir: Implications for earlier genotyping and regimen optimisation. [PDF]

S Afr J Infect Dis
Naidoo S.
europepmc   +1 more source

Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation. [PDF]

Ann Epidemiol
Zheng A, Fox MP, Greener R, Kileel EM, Bor J, Venter WD, Pisa PT, Murray EJ, Brennan AT, Maskew M.   +9 more
europepmc   +1 more source

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV [PDF]

, 2014

core   +1 more source

A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens. [PDF]

J Antimicrob Chemother
Dickinson L, Else L, Venter WDF, Boffito M, Brand R, Waitt C, Hill A, Khoo S.   +7 more
europepmc   +1 more source

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation [PDF]

, 2016

core   +1 more source

A cross-sectional study of viral load suppression among youth living with HIV in Namibia. [PDF]

South Afr J HIV Med
Kamangu JWN, Mboweni SH.
europepmc   +1 more source

Brief Report: Dolutegravir-Based Therapy, Diet, Physical Activity, and Weight Gain: A 48-week Prospective Cohort in South Africa. [PDF]

J Acquir Immune Defic Syndr
Tien D, Chandiwana N, Shazi G, Chen G, Mabweazara S, Moosa MS, Gupta RK, Pillay D, Marconi VC, Hedt-Gauthier B, Venter WDF, Siedner MJ, McCluskey SM, Manne-Goehler J.   +13 more
europepmc   +1 more source

HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. [PDF]

J Antimicrob Chemother
Schönenberger CM, Haenggi K, Ringera IK, Luoga E, Bresser M, Mothobi B, Mokhele K, Sando D, Molatelle M, Thahane L, Mnzava D, Ndege R, Hlasoa MM, Kayembe BP, Muhairwe J, Glass TR, Klimkait T, Weisser M, Labhardt ND, Tschumi N, Brown JA.   +20 more
europepmc   +1 more source